A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

• Richard N Greenberg ,

  * E-mail: Rngree01@uky.edu

  Affiliation University of Kentucky School of Medicine, Lexington, KY, United States of America

  ⨯
• Yadira Hurley,

  Affiliation Saint Louis University, Department of Dermatology, Saint Louis, MO, United States of America

  ⨯
• Dinh V. Dinh,

  Affiliation Rx Clinical Research, Inc., Garden Grove, CA, United States of America

  ⨯
• Serena Mraz,

  Affiliation Vallejo Dermatology Office, Vallejo, CA, United States of America

  ⨯
• Javier Gomez Vera,

  Affiliation Hospital Regional Lic. Adolfo Lopez Mateos, ISSSTE, Mexico City, Mexico

  ⨯
• Dorothea von Bredow,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Alfred von Krempelhuber,

  Current address: GlaxoSmithKline GmbH & Co., München, Germany

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Siegfried Roesch,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Garth Virgin,

  Current address: Vifor Pharma Ltd, Glattbrugg, Switzerland

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Nathaly Arndtz-Wiedemann,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Thomas Peter Meyer,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Darja Schmidt,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Richard Nichols,

  Current address: NewLink Genetics / BioProtection Systems, München, Germany

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Philip Young,

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯
• Paul Chaplin

  Affiliation Bavarian Nordic GmbH, Martinsried, Germany

  ⨯